摘要
目的观察重组人干扰素α-2b注射液雾化吸入治疗小儿呼吸道合胞病毒肺炎(RSVP)的临床疗效。方法选取2017年6月—2020年1月广东省江门市新会区妇幼保健院儿科收治的RSVP患儿89例,采用随机数字表法分为研究组45例和对照组44例。对照组给予孟鲁司特钠咀嚼片治疗,研究组在其基础上给予干扰素α-2b注射液雾化吸入治疗,2组患儿连续治疗7 d。比较2组患儿临床症状改善时间、临床疗效、治疗前后白介素-4(IL-4)及干扰素-γ(IFN-γ)水平。结果研究组患儿肺部啰音、咳嗽、喘憋、呼吸困难消失时间及住院时间均短于对照组(P<0.05);研究组患儿临床总有效率为97.78%,明显高于对照组的84.09%,差异有统计学意义(χ^(2)=5.094,P=0.024)。治疗7 d后,2组患儿IL-4水平均低于治疗前,IFN-γ水平均高于治疗前,且研究组降低/升高幅度大于对照组(P<0.05)。结论重组人干扰素α-2b治疗小儿RSVP可显著改善患儿临床症状,提高疗效,改善细胞因子水平。
Objective To observe the clinical effect of recombinant human interferonα-2b injection aerosol inhalation in the treatment of pediatric respiratory syncytial virus pneumonia(RSVP)in children.Methods A total of 89 children with RSVP who were admitted to the Department of Pediatrics,Jiangmen Xinhui District Maternal and Child Health Care Hospital,Guangdong Province,from June 2017 to January 2020 were selected and divided into study group(n=45)and control group(n=44)by random number table method.The control group was given montelukast sodium chewable tablets,and the research group was given interferonα-2b injection atomization inhalation therapy on the basis of montelukast sodium chewable tablets,and the 2 groups were treated for 7 days continuously.The clinical symptom improvement time,clinical efficacy,interleukin-4(IL-4)and interferon-γ(IFN-γ)levels before and after treatment were compared between 2 groups.Results The disappearance time of pulmonary rales,cough,wheezing and dyspnea and hospitalization time were shorter in the study group than in the control group,the difference were statistically significant(P<0.05).The total clinical effective rate in the study group was 97.78%,which was significantly higher than 84.09%in the control group,the difference was statistically significant(χ^(2)=5.094,P=0.024).After 7 days of treatment,IL-4 levels in 2 groups were lower than before,and IFN-γ levels were higher than before,and the decrease/increase in the study group was greater than that in the control group,the differences were statistically significant(P<0.05).Conclusions RSVP treatment with recombinant human interferonα-2b can significantly improve the clinical symptoms,efficacy and cytokine levels.
作者
吴思航
陈美霞
方文
黎炳祥
WU Sihang;CHEN Meixia;FANG Wen;LI Bingxiang(Department of Pediatrics,Jiangmen Xinhui District Maternal and Child Health Care Hospital,Guangdong Province,Jiangmen 529100,China;不详)
出处
《临床合理用药杂志》
2022年第7期38-40,共3页
Chinese Journal of Clinical Rational Drug Use
